Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 May 17;11:29. doi: 10.1186/s40164-022-00282-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 6 — Chidamide plus apatinib impact the glucose metabolism independent of the mitochondrial activity and perturb the VEGFR signaling. A, B Examination of the mitochondrial respiration and glycolytic function in CD34⁺CD38⁻ KG1α cells treated with chidamide and apatinib alone or in combination. C Western blotting analysis of the expression levels of the indicated proteins in CD34⁺CD38⁻ KG1α and primary AML cells exposed to designated doses of apatinib and chidamide alone or in combination. Apa and Chi represent apatinib and chidamide, respectively. D Immunohistochemistry analysis of the exprssion levels of VEGFR, BCL2 and MCL1 in both spleen (left panel) and bone marrow (right panel) in AML PDX mice administered with vehicle, chidamide, apatinib, or the combined treatment groups. E, F Quantification of the protein levels of VEGFR, BCL2 and MCL1 in spleen (E) and bone marrow (F) in AML PDX mice administered with distinct treatment groups. Apa, Chi and Combo represent apatinib, chidamide and the combination of the two drugs, respectively. *, ** and *** indicates p < 0.05, p < 0.01, p < 0.001, respectively. ns indicates not significant